Marvel Biosciences Corp (TSE:MRVL)
:MRVL
Total Valuation
Marvel Biosciences Corp has a market cap or net worth of C$8.12M. The enterprise value is C$10.16M.
Market CapC$8.12M
Enterprise ValueC$10.16M
Share Statistics
Marvel Biosciences Corp has 58,004,482 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,004,482
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Marvel Biosciences Corp’s return on equity (ROE) is 0.55 and return on invested capital (ROIC) is 73.61%.
Return on Equity (ROE)0.55
Return on Assets (ROA)-6.77
Return on Invested Capital (ROIC)73.61%
Return on Capital Employed (ROCE)0.31
Revenue Per Employee0.00
Profits Per Employee-442.29K
Employee Count5
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Marvel Biosciences Corp is ―. Marvel Biosciences Corp’s PEG ratio is 0.04.
PE Ratio―
PS Ratio0.00
PB Ratio-2.07
Price to Fair Value-2.07
Price to FCF-7.20
Price to Operating Cash Flow-5.51
PEG Ratio0.04
Income Statement
In the last 12 months, Marvel Biosciences Corp had revenue of 0.00 and earned -2.21M in profits. Earnings per share was -0.05.
Revenue0.00
Gross Profit-547.37K
Operating Income-1.25M
Pretax Income-2.21M
Net Income-2.21M
EBITDA-1.94M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was -1.47M and capital expenditures 6.00, giving a free cash flow of -1.47M billion.
Operating Cash Flow-1.47M
Free Cash Flow-1.47M
Free Cash Flow per Share-0.03
Dividends & Yields
Marvel Biosciences Corp pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.21
52-Week Price Change40.00%
50-Day Moving Average0.14
200-Day Moving Average0.18
Relative Strength Index (RSI)44.69
Average Volume (3m)89.38K
Important Dates
Marvel Biosciences Corp upcoming earnings date is Jun 23, 2026, After Close (Confirmed).
Last Earnings DateMar 31, 2026
Next Earnings DateJun 23, 2026
Ex-Dividend Date―
Financial Position
Marvel Biosciences Corp as a current ratio of 0.08, with Debt / Equity ratio of -59.86%
Current Ratio0.08
Quick Ratio0.08
Debt to Market Cap0.28
Net Debt to EBITDA-1.12
Interest Coverage Ratio-4.66
Taxes
In the past 12 months, Marvel Biosciences Corp has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Marvel Biosciences Corp EV to EBITDA ratio is -5.38, with an EV/FCF ratio of -9.09.
EV to Sales0.00
EV to EBITDA-5.38
EV to Free Cash Flow-9.09
EV to Operating Cash Flow-9.09
Balance Sheet
Marvel Biosciences Corp has C$274.17K in cash and marketable securities with C$2.31M in debt, giving a net cash position of -C$2.04M billion.
Cash & Marketable SecuritiesC$274.17K
Total DebtC$2.31M
Net Cash-C$2.04M
Net Cash Per Share-C$0.04
Tangible Book Value Per Share-C$0.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Marvel Biosciences Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―